Clozapine inhibits catalepsy induced by olanzapine and loxapine, but prolongs catalepsy induced by SCH 23390 in rats

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 355, Issue 3, 1997, Pages 361-364

  Kalkman, H O ^a   Neumann, V ^a   Tricklebank, M D ^a  

^a Sandoz Pharma Ltd   (Switzerland)

Author keywords

Catalepsy; Clozapine; Loxapine; Olanzapine; SCH 23390

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; CLOZAPINE; LOXAPINE; OLANZAPINE;

ANIMAL MODEL; ARTICLE; CATALEPSY; CONTROLLED STUDY; DOSE RESPONSE; MALE; NONHUMAN; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030991805     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00004955     Document Type: Article

References (25)

1. Anderson JJ, Randall S, Chase TN (1995) The neurokinin1 receptor antagonist CP-99,994 reduces catalepsy produced by the dopamine D2 receptor antagonist raclopride: correlation with extracellular acetylcholine levels in striatum. J Pharmacol Exp Ther 274:928-936
2. Baldessarini RJ, Centorrino F, Flood JG, Volpicelli SA, Huston-Lyons D, Cohen BM (1993) Tissue concentrations of clozapine and its metabolites in the rat. Neuropsychopharmacology 9:117-124
3. Baldessarini RJ, Tarsy D (1980) Dopamine and the pathophysiology of dyskinesias induced by antipsychotic drugs. Ann Rev Neurosci 3:23-41
4. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87-96
5. Casey DE (1989) Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology [Suppl.] 99:47-53
6. Claghorn J, Honigfeld G, Abuzzahab F, Wang R, Steinbook R, Tuason V, Klerman G (1987) The risk and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 7:377-384
7. Erevalo GJG, Gershanik OS (1993) Modulatory effect of clozapine on levodopa response in Parkinson's disease: a preliminary study. Mov Disord 8:349-354
8. Fischer-Cornelssen KA, Ferner UJ (1976) An example of European multicenter trials: multispectral analysis of clozapine. Psychol Bull 12:34-39
9. Hoffman DC, Donovan H (1995) Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacology 120:128-133
10. Iorio LC, Barnett A, Leitz FH, Houser VP, Korduba CA (1983) SCH 23390, a potential benzazepine antipsychotic with unique interaction on dopaminergic systems. J Pharmacol Exp Ther 226:462-468
11. Juul Povlsen U, Norig U, Fog R, Gerlach J (1985) Tolerability and therapeutic effect of clozapine. A retrospective investigation of 216 patients treated with clozapine for up to 12 years. Acta Psychiatr Scand 71:176-185
12. Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for treatment-resistant schizophrenic. Arch Gen Psychiatry 45:789-796
13. Klemm WR, Block H (1988) D-1 and D-2 receptor blockade have additive cataleptic effects in mice, but receptor effects may interact in opposite ways. Pharmacol Biochem Behav 29:223-229
14. i values. J Pharmacol Exp Ther 251:238-246
15. Moore NA, Calligaro DO, Wong DT, Bymaster F, Tye NC (1993) The pharmacology of olanzapine and other new antipsychotic agents. Curr Opin Invest Drugs 2:281-293
16. Morelli M, Di Chiara G (1985) Catalepsy induced by SCH 23390 in rats. Eur J Pharmacol 117:179-185
17. Papa SM, Engber TM, Boldry RC, Chase TN (1993) Opposite effects of NMDA and AMPA receptor blockade on catalepsy induced by dopamine receptor antagonists. Eur J Pharmacol 232:247-253
18. Schmutz J, Eichenberger E (1982) Clozapine. In: Bindra JS, Hednicer D (eds) Chronicles of drug discovery. John Wiley & Sons, Chichester, pp 39-59
19. Sebens JB, Koch T, Ter Horst GJ, Korf J (1995) Differential Fos-protein induction in rat forebrain regions after acute and long-term haloperidol and clozapine treatment. Eur J Pharmacol 273:175-182
20. Shopsin B, Klein H, Aaronson M, Collora M (1979) Clozapine, chlorpromazine, and placebo in newly hospitalized, acutely schizophrenic patients. Arch Gen Psychiatry 36:657-664
21. 2 receptor subtypes. J Psychiatry Neurosci 21:29-35
22. 2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral electrophysiological and neurochemical studies. J Pharmacol Exp Ther 266:684-691
23. 2 receptor binding of antipsychotics in vivo. Pharmacol Biochem Behav 49:165-169
24. 2 dopamine and N-methyl-D-aspartate (NMDA) receptor participation in experimental catalepsy in rats. Psychopharmacology 109:477-483
25. Wadenberg ML (1992) Antagonism by 8-OH-DPAT, but not ritanserin, of catalepsy induced by SCH 23390 in the rat. J Neural Transm 89:49-59